Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs HuMax TF ADC (Primary)
- Indications Bladder cancer; Cervical cancer; Endometrial cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Genmab
- 10 Jun 2017 Biomarkers information updated
- 02 Mar 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2017.
- 23 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.